In pre-satiated rats, CBG increased food intake and meal frequency without neuromotor side effects. This is a single preclinical result; appetite effects have not been studied in humans.
The grade weighs the claim as a whole, across every study our registry holds on the question. How good any one of those papers is remains a separate matter, and you can judge each on its own terms.
animal model (Lister hooded rats; feeding microstructure) · animal
One trial is running now. Someone is putting the question to the test, and that alone sets it apart from the questions nobody has asked. A registration is not evidence, though, and none of the records below changes the grade above.
Pain, Appetite loss
Source: ClinicalTrials.gov, retrieved 2026-08-31. A completed trial marked no publication located is one our search came up empty on, and searches by trial identifier are known to miss papers. So we write “never published” only when we have positive evidence for it.
The CBG monograph covers the compound end to end, and the gap-map charts the questions nobody has tested yet.
CBG acts on α2-adrenoceptors, which help regulate blood pressure; anyone taking cardiovascular medication should consult a clinician before using CBG products. Nothing on this page is medical advice, and no statement here is a claim that CBG treats, cures, or prevents any condition. Grades are based on the studies we had checked as of 9 August 2026. Report a safety event. Peregrine Biopharma funds the platform and holds no editorial authority.